

Title: Regional Differences in the US in Outcomes with Preeclampsia

Authors: Aardra Rajendran MD^a, Yisi Liu, MHS^b, Theresa M. Boyer MS MSPH^c, Arthur J. Vaught MD^{d,e}, Allison G. Hays MD^{f,g}, Josef Coresh, MD PhD^c, Dhananjay Vaidya, MBBS PhD MPH^h, Erin D. Michos MD MHS^{f,g}, Anum S. Minhas MD MHS^{f,g}

Author Affiliations:

^aDepartment of Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA

^bDepartment of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA

^cDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

^dDivision of Maternal Fetal Medicine, Department of Gynecology and Obstetrics, Johns Hopkins University, Baltimore, Maryland

^eDivision of Acute Care and Adult Trauma Surgery, Department of Surgery, Johns Hopkins University, Baltimore, Maryland

^fDivision of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA

^gCiccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

^hDivision of General Internal Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Address for Correspondence:

Aardra Rajendran, MD
1800 Orleans Street, Carnegie 591A
Baltimore, MD 21287
Phone: 9082299788
Email: arajend2@jh.edu
Twitter: @AardraRajendran

Word Count

Total (<800): 791

References (≤5): 5

Disclosures:

Funding: Dr. Minhas is supported by NIH KL2TR003099. Dr. Michos is supported by the Amato Fund in Women's Cardiovascular Health Research. Theresa Boyer is supported by National, Heart, Lung, and Blood Institute grant T32HL007024.

Acknowledgements: The authors are grateful to the women who chose to participate in the Preeclampsia Registry and to the Preeclampsia Foundation for providing the data.

Abstract

This study explores preeclampsia outcomes across US regions and examines regional differences in specific preeclampsia-associated pregnancy complications and disease management. Patient-reported measures were obtained from The Preeclampsia Registry, an open-access database composed of women with at least one pregnancy diagnosed with a hypertensive disorder of pregnancy. Pregnancies and associated outcomes were stratified by US region (Northeast, Midwest, South and West). Among 2,667 pregnancies of which 92% were in White women, maximum systolic blood pressure at any time in pregnancy was highest among women in the South and Midwest ($p=0.039$). Furthermore, more women in the South received pre-pregnancy anti-hypertensives ($p=0.026$) and antenatal steroids ($p=0.025$) and delivered at an earlier gestational age ($p=0.014$) compared to women in other regions. Pregnancy complications such as elevated liver enzymes were higher in women in the South ($p=0.019$), and women in the South and West had additional end-organ damage such as renal complications ($p<0.001$) and hemolysis ($p=0.008$) as compared to women in other regions. Further investigation is needed to assess whether healthcare access or policy could be contributing to these regional discrepancies.

Introduction

Preeclampsia affects 2-8% of all pregnancies and is associated with adverse maternal-fetal outcomes and increased cardiovascular disease risk. Studies have demonstrated regional geographic differences in the prevalence of preeclampsia in the United States (US). Women in the South are at higher risk for developing preeclampsia and have an

increased risk of maternal mortality compared to women in the Northeast (1,2). In this study, we aim to gain a deeper understanding of preeclampsia outcomes across US regions and examine regional differences in specific preeclampsia-associated pregnancy complications and disease management.

Methods

Retrospective deidentified patient-reported measures were obtained from The Preeclampsia Registry (TPR), an open-access database composed of women with at least one pregnancy diagnosed with a hypertensive disorder of pregnancy (HDP) (chronic hypertension, gestational hypertension, preeclampsia, eclampsia, or chronic hypertension with superimposed preeclampsia or eclampsia). Participants self-reported their diagnosis of HDP and personal, family, medical, and pregnancy history, including clinical measures and laboratory data through an online questionnaire. Elevated liver enzymes, renal complications, hemolysis, and thrombocytopenia were defined by standard of care laboratory measurements. Self-reported outcomes in TPR were obtained using well-validated instruments (data harmonization criteria established by Co-Lab, obstetric data definitions validated by ACOG, and common data points suggested by the Women's Health Registries Alliance)(3). Approximately 40% of patients self-enrolled after finding TPR through an internet search and an additional 25% were recruited through foundation events. Greater than 90% of pregnancies occurred after 2003 and <1% occurred before 1984, thereby ensuring that the majority of pregnancies and their management reflect current health practices. Patients were asked to provide annual updates following registry inclusion; however, follow-up data

was not analyzed given limited availability. In this study, only pregnancies with preeclampsia were included in analysis and data were grouped by US region as defined by the US Census: Northeast, Midwest, South and West. Clinical outcomes were compared across regions using Chi-square test.

Results

Among 2,667 pregnancies, mean maternal age at delivery was 29.6 ± 5.2 years and 92% of women were White (Table 1). Maximum systolic blood pressure at any time during pregnancy was higher in women in the South (185[170-201] mmHg) and Midwest (185[168-202] mmHg) compared to women in the Northeast (182.5[160-200] mmHg) and the West (180[165-200] mmHg, $p=0.039$). Prior to pregnancy, more women in the South were taking anti-hypertensive medications (16.8%) compared to women in the Northeast (7.5%, $p=0.026$). During pregnancy, prevalence of anti-hypertensive use was higher in the South (31.3%) compared to the Northeast (24.6%), although the difference did not reach statistical significance. Women in the South had the earliest gestational age at delivery (33.8 ± 4.7 weeks) while women in the Northeast had the latest gestational age (34.5 ± 4.3 weeks, $p=0.014$), and furthermore, more women in the South required antenatal steroids for preterm delivery (12.3%) compared to women in the Northeast (7.9%, $p=0.025$). Preeclampsia-associated pregnancy complications, including elevated liver enzymes, renal complications, and hemolysis, were generally higher among women in the West and South as compared to women in the Midwest and Northeast. There were no significant differences in the rates of Caesarean-section across regions (68.8% Northeast; 67.4% South).

Discussion

This study suggests that preeclampsia-associated pregnancy complications may be greater among women in the South, thus building on prior findings that women in the South are at higher risk of developing preeclampsia compared to women in the Northeast (1). Women were more likely to require anti-hypertensive medications prior to pregnancy and had higher maximum blood pressure during pregnancy compared to women in the Northeast. They also delivered at an earlier gestational age and had increased requirements for antenatal steroid use. Lastly, women in the South and West had more preeclampsia-associated end-organ damage as compared to women in the Northeast and Midwest.

These regional differences could potentially be attributable to differences in preeclampsia risk factors, demographic factors, and/or socioeconomic disparities related to healthcare access. BMI data was unavailable in this dataset; however, obesity is an important risk factor for the development of preeclampsia and its prevalence has been increasing over the years, particularly in the South (4). Furthermore, obesity rates are highest in non-Hispanic Black women, and Black women independently have higher incidences of preeclampsia and preeclampsia-associated complications (5). Increased adverse pregnancy outcomes in the South may also be due to decreased prenatal care and birthing facilities (2).

This study represents data from across the US and is not limited by institutional or targeted recruitment. Importantly, it includes patient-reported outcomes; however, as participation is voluntary, selection bias is possible. Additionally, the majority of women

enrolled are White, and analyses between regional differences and race/ethnicity was not performed due to sample size limitations. Nonetheless, we find differences in key clinical outcomes and variables by geographic region in the US. Future studies should be performed to investigate whether variations in healthcare access or policy could explain regional disparities.

Table 1. Preeclampsia Participant Demographics and Clinical Outcomes, Stratified by US Census Region

	Total	Northeast	Midwest	South	West	p-value
	N=2,667	N=542	N=628	N=907	N=590	
Age at delivery, years	29.5 ± 5.2	30.4 ± 5.2	29.0 ± 5.0	29.1 ± 5.0	29.8 ± 5.5	<0.001
Gestational age at delivery, weeks	34.2 ± 4.6	34.5 ± 4.3	34.1 ± 4.6	33.9 ± 4.7	34.5 ± 4.4	0.014
Race						
White	2,415 (91.6%)	492 (92.3%)	589 (94.7%)	832 (92.2%)	502 (86.6%)	<0.001
Black	47 (1.8%)	13 (2.4%)	7 (1.1%)	22 (2.4%)	5 (0.9%)	
Highest completed educational level						
High school	44 (4.4%)	8 (3.8%)	10 (4.1%)	17 (5.0%)	9 (4.3%)	0.67
College	608 (60.6%)	119 (56.7%)	154 (62.6%)	212 (62.7%)	123 (58.9%)	
Graduate school	345 (34.4%)	81 (38.6%)	81 (32.9%)	106 (31.4%)	77 (36.8%)	
Gestational age at initiation of prenatal care						
<8 weeks	1,782 (66.9%)	379 (69.9%)	394 (62.8%)	622 (68.6%)	387 (65.7%)	0.029
8-12 weeks	806 (30.2%)	150 (27.7%)	216 (34.4%)	255 (28.1%)	185 (31.4%)	
13-16 weeks	48 (1.8%)	9 (1.7%)	13 (2.1%)	19 (2.1%)	7 (1.2%)	
Medication use prior to pregnancy						
Antihypertensive	82 (13.3%)	10 (7.5%)	23 (16.5%)	38 (16.8%)	11 (9.3%)	0.026
Aspirin	81 (20.6%)	13 (17.6%)	23 (24.5%)	22 (20.0%)	23 (20.0%)	0.72
Diabetes medications	54 (37.0%)	12 (46.2%)	15 (40.5%)	19 (36.5%)	8 (25.8%)	0.42
Preeclampsia Outcomes						
Antihypertensive	184 (29.0%)	32 (24.6%)	41 (28.5%)	73 (31.3%)	38 (29.9%)	0.59
Antenatal steroid	262 (10.2%)	41 (7.9%)	57 (9.4%)	109 (12.3%)	55 (9.7%)	0.025
Maximum systolic blood pressure, mmHg	183 [166-200]	182 [160-200]	185 [168-202]	185 [170-201]	180 [165-200]	0.039
Maximum diastolic blood pressure, mmHg	110 [100-120]	110 [100-119]	110 [100-120]	110 [100-120]	110 [100-115]	0.038
Elevated liver enzymes	1,493 (56.3%)	301 (55.5%)	340 (54.5%)	527 (58.4%)	325 (55.6%)	0.019
Renal complication	498 (18.8%)	93 (17.2%)	94 (15.0%)	177 (19.6%)	134 (22.9%)	<0.001
Hemolysis	654 (24.7%)	115 (21.3%)	146 (23.4%)	229 (25.4%)	164 (28.0%)	0.008
Low platelets	1,155 (43.5%)	222 (41.0%)	268 (42.9%)	400 (44.4%)	265 (45.1%)	0.64
Intensive care unit stay	439 (16.6%)	96 (18.0%)	85 (13.7%)	162 (18.0%)	96 (16.4%)	0.078
Cesarean section	1,774 (65.0%)	384 (68.8%)	412 (63.2%)	617 (67.4%)	361 (59.8%)	0.07

Continuous variables are presented as mean ± standard deviation if normally distributed and median [25th – 75th percentiles] if non-normally distributed. Categorical variables are listed as number (percentage).

* Data in each category are only presented for women with available values.

REFERENCES

1. Wallis AB, Saftlas AF, Hsia J, Atrash HK. Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987–2004. *American journal of hypertension* 2008;21:521-526.
2. Snyder JE, Stahl AL, Streeter RA, Washko MM. Regional variations in maternal mortality and health workforce availability in the United States. *Annals of internal medicine* 2020;173:S45-S54.
3. The Preeclampsia Registry (TPR); NCT02020174. Preeclampsia Foundation, 2013. <https://clinicaltrials.gov/study/NCT02020174> (2022-10-22).
4. Wang Y, Beydoun MA. The obesity epidemic in the United States—gender, age, socioeconomic, racial/ethnic, and geographic characteristics: a systematic review and meta-regression analysis. *Epidemiologic reviews* 2007;29:6-28.
5. Gyamfi-Bannerman C, Pandita A, Miller EC et al. Preeclampsia outcomes at delivery and race. *The Journal of Maternal-Fetal & Neonatal Medicine* 2020;33:3619-3626.

Table 1. Preeclampsia Participant Demographics and Clinical Outcomes, Stratified by US Census Region

	Total	Northeast	Midwest	South	West	p-value
	N=2,667	N=542	N=628	N=907	N=590	
Age at delivery, years	29.5 ± 5.2	30.4 ± 5.2	29.0 ± 5.0	29.1 ± 5.0	29.8 ± 5.5	<0.001
Gestational age at delivery, weeks	34.2 ± 4.6	34.5 ± 4.3	34.1 ± 4.6	33.9 ± 4.7	34.6 ± 4.4	0.014
Race						
Whites	2,415 (91.6%)	492 (92.3%)	589 (94.7%)	832 (92.2%)	502 (86.6%)	<0.001
Black	47 (1.8%)	13 (2.4%)	7 (1.1%)	22 (2.4%)	5 (0.9%)	
Highest completed educational level						
High school	44 (4.4%)	8 (3.8%)	10 (4.1%)	17 (5.0%)	9 (4.3%)	0.67
College	606 (60.8%)	119 (56.7%)	154 (82.6%)	212 (82.7%)	123 (58.9%)	
Graduate school	345 (34.4%)	81 (38.6%)	81 (32.9%)	106 (31.4%)	77 (36.8%)	
Gestational age at initiation of prenatal care						
<8 weeks	1,782 (66.9%)	379 (69.9%)	394 (62.8%)	622 (68.6%)	387 (65.7%)	0.029
8-12 weeks	806 (30.2%)	150 (27.7%)	216 (34.4%)	255 (28.1%)	185 (31.4%)	
13-18 weeks	48 (1.8%)	9 (1.7%)	13 (2.1%)	19 (2.1%)	7 (1.2%)	
Medication use prior to pregnancy						
Antihypertensive	82 (13.3%)	10 (7.5%)	23 (16.5%)	38 (16.8%)	11 (9.3%)	0.026
Aspirin	81 (20.6%)	13 (17.6%)	23 (24.5%)	22 (20.0%)	23 (20.0%)	0.72
Diabetes medications	54 (37.0%)	12 (40.2%)	15 (40.5%)	19 (36.5%)	8 (25.8%)	0.42
Preeclampsia Outcomes						
Antihypertensive	184 (29.0%)	32 (24.6%)	41 (28.5%)	73 (31.3%)	38 (29.9%)	0.59
Antenatal steroid	262 (10.2%)	41 (7.9%)	57 (9.4%)	109 (12.3%)	55 (9.7%)	0.025
Maximum systolic blood pressure, mmHg	183 [168-200]	182 [165-200]	185 [168-202]	185 [170-201]	180 [165-200]	0.039
Maximum diastolic blood pressure, mmHg	110 [100-120]	110 [100-119]	110 [100-120]	110 [100-120]	110 [103-116]	0.038
Elevated liver enzymes	1,493 (56.3%)	301 (55.5%)	340 (54.5%)	527 (58.4%)	325 (55.6%)	0.019
Renal complication	498 (18.8%)	93 (17.2%)	94 (15.0%)	177 (19.6%)	134 (22.9%)	<0.001
Hemolysis	654 (24.7%)	115 (21.3%)	146 (23.4%)	229 (25.4%)	164 (28.0%)	0.098
Low platelets	1,155 (43.5%)	222 (41.0%)	268 (42.9%)	400 (44.4%)	265 (45.1%)	0.64
Intensive care unit stay	439 (16.8%)	95 (18.0%)	85 (13.7%)	162 (18.0%)	96 (16.4%)	0.076
Cesarean section	1,774 (66.5%)	354 (68.8%)	412 (63.2%)	617 (67.4%)	361 (58.8%)	0.07

Continuous variables are presented as mean ± standard deviation if normally distributed and median [25th – 75th percentiles] if non-normally distributed. Categorical variables are listed as number (percentage).

* Data in each category are only presented for women with available values.